Episodic Memory

Every compound in the sci-wiki that affects episodic memory; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.

0 sourced · 2 reference

←episodic memory2/2

Nootropic

Farampator

Farampator (CX-691 / Org 24448) is an investigational ampakine, a positive allosteric modulator of AMPA-type glutamate receptors, advanced through the Cortex Pharmaceuticals / Organon program. It slows AMPA-receptor deactivation and desensitization to strengthen fast excitatory transmission and long-term potentiation, and in animals it raises hippocampal and prefrontal acetylcholine, prefrontal dopamine, and hippocampal BDNF mRNA. It is best known for a single, unusually instructive human trial in which one 500 mg dose improved short-term memory yet impaired episodic memory in healthy elderly volunteers.

reference

Nootropic

Ispronicline

Ispronicline traces its chemistry back to nicotine research originally funded by tobacco company R.J. Reynolds, which spun off its pharmaceutical research arm into Targacept in the late 1990s. The resulting compound was a partial agonist at alpha4beta2 neuronal nicotinic receptors, designed to capture nicotine's attention- and memory-enhancing effects without its addictive and cardiovascular baggage. AstraZeneca partnered with Targacept and pushed ispronicline (as AZD3480) into a Phase IIb dose-finding trial for mild-to-moderate Alzheimer's disease as well as separate studies for adult ADHD. The Alzheimer's trial, published in 2011, failed to show a robust cognitive benefit, and AstraZeneca discontinued the partnership around 2010-2011, part of a broader collapse of the nicotinic-receptor cognition-enhancement field that also claimed several competing programs.

reference